| Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional … DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ... Journal of Clinical Oncology 37 (18), 1558, 2019 | 1047 | 2019 |
| Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic … DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ... The lancet oncology 17 (12), 1672-1682, 2016 | 1025 | 2016 |
| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 936 | 2022 |
| PDL1 Regulation by p53 via miR-34 MA Cortez, C Ivan, D Valdecanas, X Wang, HJ Peltier, Y Ye, L Araujo, ... Journal of the National Cancer Institute 108 (1), djv303, 2016 | 614 | 2016 |
| An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer AB Ashworth, S Senan, DA Palma, M Riquet, YC Ahn, U Ricardi, ... Clinical lung cancer 15 (5), 346-355, 2014 | 451 | 2014 |
| Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document Y Lievens, M Guckenberger, D Gomez, M Hoyer, P Iyengar, I Kindts, ... Radiotherapy and Oncology 148, 157-166, 2020 | 436 | 2020 |
| Scientific advances in lung cancer 2015 AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone, GW Warren, C Bai, ... Journal of Thoracic Oncology 11 (5), 613-638, 2016 | 339 | 2016 |
| Delta-radiomics features for the prediction of patient outcomes in non–small cell lung cancer X Fave, L Zhang, J Yang, D Mackin, P Balter, D Gomez, D Followill, ... Scientific reports 7 (1), 588, 2017 | 336 | 2017 |
| Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes C Tang, Z Liao, D Gomez, L Levy, Y Zhuang, RA Gebremichael, DS Hong, ... International Journal of Radiation Oncology* Biology* Physics 89 (5), 1084-1091, 2014 | 329 | 2014 |
| Combining radiation and immunotherapy: a new systemic therapy for solid tumors? C Tang, X Wang, H Soh, S Seyedin, MA Cortez, S Krishnan, E Massarelli, ... Cancer immunology research 2 (9), 831-838, 2014 | 318 | 2014 |
| Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non–small-cell lung cancer Z Liao, JJ Lee, R Komaki, DR Gomez, MS O’Reilly, FV Fossella, ... Journal of Clinical Oncology 36 (18), 1813, 2018 | 310 | 2018 |
| Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells C Tang, JW Welsh, P De Groot, E Massarelli, JY Chang, KR Hess, S Basu, ... Clinical Cancer Research 23 (6), 1388-1396, 2017 | 303 | 2017 |
| Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly SM Shirvani, J Jiang, JY Chang, JW Welsh, DR Gomez, S Swisher, ... International Journal of Radiation Oncology* Biology* Physics 84 (5), 1060-1070, 2012 | 295 | 2012 |
| Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone” JY Chang, QQ Li, QY Xu, PK Allen, N Rebueno, DR Gomez, P Balter, ... International Journal of Radiation Oncology* Biology* Physics 88 (5), 1120-1128, 2014 | 263 | 2014 |
| Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer EJ Moding, Y Liu, BY Nabet, JJ Chabon, AA Chaudhuri, AB Hui, ... Nature Cancer 1 (2), 176-183, 2020 | 244 | 2020 |
| Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma M Rivera, RA Ghossein, H Schoder, D Gomez, SM Larson, RM Tuttle Cancer 113 (1), 48-56, 2008 | 230 | 2008 |
| Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy X Wang, JE Schoenhals, A Li, DR Valdecanas, H Ye, F Zang, C Tang, ... Cancer research 77 (4), 839-850, 2017 | 221 | 2017 |
| Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy R Davuluri, W Jiang, P Fang, C Xu, R Komaki, DR Gomez, J Welsh, ... International Journal of Radiation Oncology* Biology* Physics 99 (1), 128-135, 2017 | 214 | 2017 |
| Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy HM Wang, ZX Liao, R Komaki, JW Welsh, MS O'reilly, JY Chang, ... Annals of oncology 24 (5), 1312-1319, 2013 | 211 | 2013 |
| Factors associated with age disparities among cancer clinical trial participants EB Ludmir, W Mainwaring, TA Lin, AB Miller, A Jethanandani, ... JAMA oncology 5 (12), 1769-1773, 2019 | 193 | 2019 |
